Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516374 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

Anti-breast cancer drug testing. Edition No. 1

VDM Publishing House, Sep 2009, Pages: 220


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

As deeper mouse model mimics original human cancer biology as more satisfactory experimental drug testing would predict it's efficacy in clinic. New mouse models of breast cancer and leukemic lymphoma are maintained in conventional (non Specific Pathogen Free) conditions to reproduce multifaceted process of cancer development as consequences of genetic predisposition and chronic inflammation interplay. Lobular and ductal mammary lesions occur in the mice naturally at multiple primary localizations mimicking corresponding preneoplastic and neoplastic human diseases. Hence, these models are clearly more adequate to familial set of human breast cancer than standard SPF models. Author's mouse models, reproducing both human cancer itself and some concurrent pathological conditions are recommended for use in preclinical research as concomitant chronic pathologies in human patients may impede anticancer drug efficacy. Indeed, both benefit and non-benefit sets of recipients were revealed during testing efficacy of interleukin-2 immunotherapy and lectin target chemotherapy using these mice. Conclusion: selection procedure for cancer patients before therapy application should be developed.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds